Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS: −19.6%
Free cash flow: −43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%

Follow ORKA

Alert me

Market cap: $6.4B
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Oruka Therapeutics, Inc. 10-K filed Mar 12, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Mar 12, 2026 · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Mar 6, 2025: 13 added · 18 removed · 120 modified; 7 moved without change